UniProtKB/Swiss-Prot Q05086: Variant p.Thr679Ile

Ubiquitin-protein ligase E3A
Gene: UBE3A
Chromosomal location: 15q11-q13
Variant information

Variant position:  679
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Unclassified
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Threonine (T) to Isoleucine (I) at position 679 (T679I, p.Thr679Ile).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (T) to medium size and hydrophobic (I)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Angelman syndrome (AS) [MIM:105830]: A neurodevelopmental disorder characterized by severe motor and intellectual retardation, ataxia, frequent jerky limb movements and flapping of the arms and hands, hypotonia, seizures, absence of speech, frequent smiling and episodes of paroxysmal laughter, open-mouthed expression revealing the tongue. {ECO:0000269|PubMed:25212744, ECO:0000269|PubMed:9585605}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In AS; unknown pathological significance.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  679
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  875
The length of the canonical sequence.

Location on the sequence:   YQSLKDLLEYEGNVEDDMMI  T FQISQTDLFGNPMMYDLKEN
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         YQSLKDLLEYEGNVEDDMMITFQISQTDLFGNPMMYDLKEN

Mouse                         YQSLKDLLEYEGSVEDDMMITFQISQTDLFGNPMMYDLKEN

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 875 Ubiquitin-protein ligase E3A
Modified residue 659 – 659 Phosphotyrosine; by ABL1
Beta strand 679 – 684


Literature citations

Mutation update for UBE3A variants in Angelman syndrome.
Sadikovic B.; Fernandes P.; Zhang V.W.; Ward P.A.; Miloslavskaya I.; Rhead W.; Rosenbaum R.; Gin R.; Roa B.; Fang P.;
Hum. Mutat. 35:1407-1417(2014)
Cited for: VARIANTS AS LYS-129; VAL-235; GLN-260; HIS-260; TRP-286; PRO-458; LEU-481; PRO-500; ARG-568; LYS-589; GLN-607; ILE-679; CYS-713 AND LEU-850; VARIANTS ARG-140; GLY-156; THR-293; THR-358; ILE-501; GLU-611; PRO-611; ARG-696 AND ILE-785;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.